Статья
Современные аспекты лечения стенокардии у больных артериальной гипертонией: акцент на функцию эндотелия
Обзор литературы посвящен анализу роли частоты сердечных сокращений (ЧСС) в патогенезе артериальной гипертонии (АГ) и ишемической болезни сердца (ИБС); ее предсказательной ценности для прогнозирования развития сердечно-сосудистых осложнений. С позиций доказательной медицины проанализированы современные тенденции фармакотерапии ИБС у больных AT I-II степеней. Рассмотрена роль воздействия антиангинальных и антигипертензивных средств на функцию эндотелия и состояние микроциркуляции у данной категории пациентов. Приведены последние данные о влиянии препаратов, замедляющих ЧСС, на течение и прогноз стабильной стенокардии. Обоснована целесообразность дальнейших исследований по определению места ивабрадина в комбинированной медикаментозной терапии сердечно-сосудистых заболеваний.
1. Карпов Ю.А., Буза В.В. Ивабрадин как новая составляющая эффективного лечения больных стабильной стенокардией. Сердце 2006; 5: 248-52.
2. Kannel W., Feinleib M. Natural hystory of angina pectoris in the Framingham Study. Prognosis and survival. Am J Cardiol 1972; 29(2):154-63.
3. Маколкин В.И., Зябрев Ф.Н. Почему надо снижать частоту сердечных сокращений при лечении стабильной стенокардии? Кардиология 2006; 9: 88-91.
4. Sigh B.N. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Ther 2001; 6: 313-31.
5. Шальнова C.A., Деев А.Д., Оганов Р.Г. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. // Кардиология. 2005. № 10. С. 45.
6. Wilhelmsen L., Berlund G., Elmfeldt D., et al. The multifactor primary prevention trial in Geteborg, Sweden. Eur Heart J 1986; 7: 279-88.
7. Карпов Ю.А., Шальнова С.А., Деев АД. от имени участников программы. Исследование ПРЕМЬЕРА: достижение целевого уровня артериального давления -успех в лечении ишемической болезни сердца. Кардиоваск тер профил 2006; 6: 53-60.
8. Dawber T.R. The Framingham study. The epidemiology of atherosclerotic disease. Cambridge: Harvard University Press 1980.
9. Nitenberg A., Antony I. Epicardial coronary arteries are not adequatly sized in hypertensive patients. JACC 1996; 27: 115-23.
10. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
11. Российские рекомендации по диагностике и лечению стабильной стенокардии. Сердце 2006; 2: 86-100.
12. Dalen J.E. Aspirin to prevent heart attack and Stroke: what's the right dose? Am J Med 2006; 119(3): 198-202.
13. Карпов Ю.А., Шубина A.T. Бета-блокаторы в лечении и профилактике ишемической болезни сердца. Сердце 2005; 1:32-5.
14. Beta-blocker Heart Attack Trial Research Group (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247: 1707-14.
15. The HOPE Study Investigators. Effects of an angitensine-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53.
16. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
17. Task Force Members, Lopez-Sendon J, Swedberg K, et al. Expert consensus document on beta-blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341-62.
18. Карпов Ю.А. Ингибиторы ангиотензинпревращающего фермента у больных ишемической болезнью сердца: при высоком риске осложнений или всем? Кардиология 2005; 9: 4-10.
19. Лопатин Ю.М. Антигипертензивные эффекты ингибитора ангиотензинпревращающего фермента периндоприла (взгляд с позиции исследования ASCOT-BPLA). Кардиоваск тер профил 2006; 3: 83-7.
20. Mancini G.B.J., Henry G.C., Macaya C. et al. Angiotensin-converting engime inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND Study. Circulation 1996; 94: 258-65.
21. Ющук E.H., Васюк Ю.А., Хадзегоева А.Б. и др. Эндотелиальная дисфункция при заболеваниях сердечно-сосудистой системы и методы ее коррекции. Клин фармак тер 2005;4: 85-90.
22. Sowers J.R. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002; 346: 1999-2001.
23. Kiowski W., Linder L., Nuesch R. Effects of angiotensin converting enzyme inhibition on endothelial vasodilatator function in primary human hypertension. Eur Heart J 1993; 14: 5-9.
24. Мареев В.Ю. Путь к исследованию EUROPA: успехи и неудачи. Серд недостат 2004; 2: 80-1.
25. Ferrari R. EUROPA: perindopril's action on markers of thrombosis, inflammation, and endothelial dysfunction in coroi artery disease. Oral presentation. A Satellite Symposium during the ESC Congress Munich 2004.
26. Ferrari R. PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction. Oral presentation. Notline session I held during the ESC Congress. Stochkgolm 2005.
27. Chillon J.C., Baumbach G.L. Effects of an angiotensin-converting enzyme inhibitor and a b-blocker on cerebral arterioles in rates. Hypertens 1999; 33: 856-61.
28. Rizzoni D., Castellano M., Porteti E. et al. Vascular structural and functional alterations before and after the development of hypertension in SHR. J Hypertens 1994; 7: 193-200.
29. Thybo N.K., Stephens N., Cooper A. et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential Hypertension. Hypertension 1995; 25: 474-81.
30. Scheidegger K.J., Wood J.V., Van Essen H. et al. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneosly hypertensive rats. J Pharmacol Exp Ther 1996; 278: 1276-81.
31. Bock P. The arterial length-densities under preventive angiotensin-converting-enzyme inhibiting treatment in the myocardium of spotaneneosly hypertensive rats. Basic Res Cardiol 1998; 93: 18-22.
32. Levy B.I., Duriez M., Samuel J.L. Coronary microvasculature alteration in hypertensive rats: effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens 2001; 14: 7-13.
33. Rakusan K., Cicutti N., Maurin A., et al. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone SHR. Microvasc Res 2000; 59: 243-54.
34. Singh B.N. Morbidity and mortality in cardiovascular disorders: impact of Reduced Heart Rate. J Cardiovasc Pharmacol Ther 2001; 6(4): 313-31.
35. Ferrari R. Editorial: heart rate. Eur Heart J 2003; 5: 1-2.
36. Kannel W., Kannel C., Paffenbarger R. et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.
37. Giflum R., Makuc D., Feldman J. Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic follow-up study. Am Heart J 1991; 121: 172-7.
38. Gillman M.W., Kannel W.B., Belanger A.D. Agostino R.B. Influence of heart rate oh mortality among persons with hypertension: the Fremingham Study. Am Heart J 1993; 125: 1148-54.
39. Белоусов Ю.Б., Ерофеева С.Б., Манешина О.А. Ивабрадин -первый If ингибитор избирательного и специфического действия, новый препарат для лечения стабильной стенокардии. Кардиология 2006; 8: 36-48.
40. DiFrancesco D., Camm A. Heart rate lowering by specific and selective If current inhibition with Ivabradin. Drugs 2004; 16(64): 1757-63.
41. Patel S., Breall J., Diver D. et al. Bradycardia is associated with development of coronary collateral vessels in humans. Coron Artery Dis 2000; 11(6): 467-72.
42. Diaz A., Bourassa M.G., Guertin M.C. et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary arteriy disease. Eur Heart J 2005; 26(10): 967-74.
43. Von Arnim T. Medical treatment to reduce total ischemic burden: total iscemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipin. TIBBS Investigators. JACC 1995; 25: 231-8.
44. Plosker G.L., Clissold S.P. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs 1992; 43: 382-414.
45. Tuomilehto J., Wikstrand J., Olsson G., et al. Decreased coronary heart disease in hypertensive smokers. Mortality results from the MARHY study. Hypertension 1989; 13: 773-80.
46. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1327-32.
47. Task Force Members., Lopez-Sendon J., Swedberg K. et al. Expert consensus document on beta-blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341-62.
48. Conn P.F., Deedwania P.C. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994; 90(2): 762-8.
49. Smith S.C., Blair S.N., Bonow R.O. et al. AHA ACC Scientific Statement: AHA ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104(13): 1577-9.
50. Guth B.D., Indolfi C., Heusch G. et al. Mechanisms of benefit in the ischemic myocardium due to heart rate reduction. Basic Res Cardiol 1990; 85:157-66.
51. Kop W.J., Verdino R.J., Gottdiener J.S. et al. Changes in heart rate and heart rate variability before ambulatory ischemic events. JACC 2001; 38: 742-9.
52. Hjalmarson A., Gilpin E., Kjekshus J. et al. Influence of heartrate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547-53.
53. Kjekshus J.K. Importance of heart rate in determining β-blocker efficacy in acute and long term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57(12): 43-9.
54. Ко D.T., Hebert P.R., Coffey C.S. et al. β-blocker therapy ahd symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351-7.
55. Lewis R.V., Lofthouse C. Adverse reaction with p-adrenoceptor blocking drugs. An update. Drug Saf 1993; 9(4): 272-9.
56. Кириченко Л.Л., Вострякова О.В., Бабич Ю.А. и др. Состояние микроциркуляции у больных артериальной гипертонией на фоне применения бета-блокаторов. Кардиоваск тер профил 2006; 6: 27-31.
57. Parenti A., Fillipi S., Amerini S. et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000; 292: 698-703.
58. Подзолков В.И., Булатов В.А. Нарушения микроциркуляции при артериальной гипертензии: причина, следствие или еще один «порочный круг»? Сердце 2005; 3: 132-7.
59. Thollon С., Cambarant С., Vian J. et al. Electrophysiological effect of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparation: comparison with UL-FS49. Br J Pharmacol 1994; 112: 37-42.
60. Vilaine J.P., Bidouard J.P., Lesage L. et al. Anti-ischemic effects of ivabradine, a selective heart rate reducing agent, in exercise induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003; 42: 688-96.
61. Monnet X., Ghaleh B., Colin P. et al. Effect of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Ext Ther 2001; 299(3): 1133-9.
62. Simon L., Ghelen B., Puybasset L. et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Ext Ther 1995; 275: 659-66.
63. Vilaine J.P., Thollon C., Villeneuve N. et al. Procoranal, a new selective If current inhibitor. Eur Heart J 2003; 5: 26-35.
64. Borer J.S., Fox K., Jaillon P., et al. Antianginal and antiischemic effects of ivabradine, an 1 (f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107(6): 821-3.
65. Weber M.A., Smith D.H., Neutel J.M., Graettinger W.F. Cardiovascular and metabolic characteristics of hypertension. Am J Med 1991; 91: 4-10.
66. Ruzyllo W., Ford I., Tendera M. et al. Antianginal and anti-ischemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina: A 3-month randomized, controlled, double-blind, multi-center trial. Eur Heart J 2004; 25(Abstract): 878.
67. Tardif J.C., Ford I., Tendera M. et al. On behalf of INITIATIVE study group. Antianginal and anti-ischemic effects of the If current inhibitor ivabradine compared to atenolol as monotherapies with chronic stable angina. A 3-month randomized, controlled, double-blind, multi-center trial. Eur Heart J 2003; 25(Abstracts): 186.
68. Lopez-Bescos L. Long-term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. Eur Heart J 2004; 25(Abstract): 876.
69. Tardif J.C., Berry С. From coronary artery disease to heart failure: potential benefits of ivabradine. Eur Heart J 2006; 8(Suppl. D): 24-9.
70. Fox K. Contribution of perindopril to cardiology: 20 years of success. Eur Heart J 2006; 9(Suppl. E): 10-9.
71. ACC/AHA/ACP-ACIM Guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force
72. PROGRESS Collaborative group. Effect of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475-84.